Helixmith Co., Ltd (084990.KQ)
KRW 2770.0
(0.0%)
KRW 2770.0
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 914.11 Million KRW | 7.7% |
| 2022 | 848.72 Million KRW | -35.75% |
| 2021 | 1.32 Billion KRW | -59.09% |
| 2020 | 3.22 Billion KRW | 3.99% |
| 2019 | 3.1 Billion KRW | 11.2% |
| 2018 | 2.79 Billion KRW | 435.92% |
| 2017 | 521.08 Million KRW | -4.17% |
| 2016 | 543.73 Million KRW | -10.32% |
| 2015 | 606.34 Million KRW | 0.0% |
| 2013 | 763.86 Million KRW | -6.02% |
| 2012 | 812.81 Million KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 925.13 Million KRW | 1.21% |
| 2024 Q2 | 838.75 Million KRW | -9.34% |
| 2023 Q1 | 956.32 Million KRW | 12.68% |
| 2023 FY | 914.11 Million KRW | 7.7% |
| 2023 Q4 | 914.11 Million KRW | 55.61% |
| 2023 Q3 | 587.45 Million KRW | -22.74% |
| 2023 Q2 | 760.32 Million KRW | -20.5% |
| 2022 Q3 | 926.89 Million KRW | -6.14% |
| 2022 Q2 | 987.54 Million KRW | -7.94% |
| 2022 Q1 | 1.07 Billion KRW | -18.8% |
| 2022 FY | 848.72 Million KRW | -35.75% |
| 2022 Q4 | 848.72 Million KRW | -8.43% |
| 2021 Q3 | 1.45 Billion KRW | -10.3% |
| 2021 Q1 | 1.72 Billion KRW | -46.53% |
| 2021 FY | 1.32 Billion KRW | -59.09% |
| 2021 Q2 | 1.62 Billion KRW | -5.94% |
| 2021 Q4 | 1.32 Billion KRW | -9.32% |
| 2020 Q4 | 3.22 Billion KRW | -6.03% |
| 2020 Q3 | 3.43 Billion KRW | -1.73% |
| 2020 Q1 | 3.44 Billion KRW | 10.8% |
| 2020 Q2 | 3.49 Billion KRW | 1.63% |
| 2020 FY | 3.22 Billion KRW | 3.99% |
| 2019 Q1 | 3.73 Billion KRW | 33.58% |
| 2019 FY | 3.1 Billion KRW | 11.2% |
| 2019 Q4 | 3.1 Billion KRW | -4.9% |
| 2019 Q3 | 3.26 Billion KRW | 25.56% |
| 2019 Q2 | 2.6 Billion KRW | -30.28% |
| 2018 Q3 | 2.68 Billion KRW | 368.54% |
| 2018 Q1 | 482.85 Million KRW | -7.34% |
| 2018 FY | 2.79 Billion KRW | 435.92% |
| 2018 Q4 | 2.79 Billion KRW | 3.92% |
| 2018 Q2 | 573.56 Million KRW | 18.78% |
| 2017 Q4 | 521.08 Million KRW | 0.0% |
| 2017 FY | 521.08 Million KRW | -4.17% |
| 2016 FY | 543.73 Million KRW | -10.32% |
| 2015 FY | 606.34 Million KRW | 0.0% |
| 2014 Q3 | 723.13 Million KRW | -2.68% |
| 2014 Q2 | 743.07 Million KRW | -6.11% |
| 2014 Q1 | 791.41 Million KRW | 3.61% |
| 2013 Q3 | 811.1 Million KRW | -0.33% |
| 2013 Q1 | 768.77 Million KRW | -5.42% |
| 2013 Q2 | 813.81 Million KRW | 5.86% |
| 2013 Q4 | 763.86 Million KRW | -5.82% |
| 2013 FY | 763.86 Million KRW | -6.02% |
| 2012 FY | 812.81 Million KRW | 0.0% |
| 2012 Q4 | 812.81 Million KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| HLB Co., Ltd. | 11.42 Billion KRW | 91.997% |
| iNtRON Biotechnology, Inc. | 1.01 Billion KRW | 9.593% |
| BINEX Co., Ltd. | 28.26 Billion KRW | 96.765% |
| Bioneer Corporation | 41.35 Billion KRW | 97.79% |
| Anterogen.Co.,Ltd. | 1.91 Billion KRW | 52.153% |
| MEDIPOST Co., Ltd. | 14.51 Billion KRW | 93.703% |
| CrystalGenomics, Inc. | 1.55 Billion USD | 41.207% |
| Chabiotech Co.,Ltd. | 34.11 Billion KRW | 97.321% |
| Medy-Tox Inc. | 59.61 Billion KRW | 98.467% |
| Peptron, Inc. | 172.18 Million KRW | -430.883% |
| Amicogen, Inc. | 46.83 Billion KRW | 98.048% |
| Genexine, Inc. | 3.8 Billion KRW | 75.988% |
| HLB Therapeutics Co.,Ltd. | 5.33 Billion KRW | 82.868% |
| LegoChem Biosciences, Inc. | 196.83 Million KRW | -364.408% |
| ALTEOGEN Inc. | 1.06 Billion KRW | 14.438% |
| PharmaResearch Co., Ltd. | 50.23 Billion KRW | 98.18% |
| SillaJen, Inc. | 1.21 Billion KRW | 24.617% |
| JETEMA, Co., Ltd. | 12.74 Billion KRW | 92.825% |
| OliX Pharmaceuticals,Inc | 468.4 Million KRW | -95.153% |
| Genomictree Inc. | 496.53 Million KRW | -84.1% |
| MedPacto, Inc. | 620.00 KRW | -147437646.452% |
| D&D Pharmatech | 3.45 Billion KRW | 73.506% |
| EASY BIO,Inc. | 25.93 Billion KRW | 96.476% |
| GI Innovation, Inc. | - KRW | -Infinity% |